Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OCGN
stocks logo

OCGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
860.00K
+12.57%
-0.058
+15%
500.00K
-66.24%
-0.060
+20%
550.00K
-59.94%
-0.057
+13.34%
Estimates Revision
The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 54.3% over the past three months. During the same period, the stock price has changed by 20.39%.
Revenue Estimates for FY2025
Revise Upward
up Image
+54.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.64%
In Past 3 Month
Stock Price
Go Up
up Image
+20.39%
In Past 3 Month
Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.240
sliders
Low
4.00
Averages
9.00
High
15.00
Current: 1.240
sliders
Low
4.00
Averages
9.00
High
15.00
Lucid Capital
Elemer Piros
Buy
initiated
$15
2025-09-30
Reason
Lucid Capital
Elemer Piros
Price Target
$15
2025-09-30
initiated
Buy
Reason
Lucid Capital analyst Elemer Piros initiated coverage of Ocugen with a Buy rating and $15 price target. Ocugen is developing next-generation, genetic medicines with the intention to save vision in genetic disorders of the eye, the analyst tells investors in a research note. The firm believes OCU400 in retinitis pigmentosa could see peak sales of $3.2B by 2032.
H.C. Wainwright
Buy
downgrade
$8 -> $7
2025-05-12
Reason
H.C. Wainwright
Price Target
$8 -> $7
2025-05-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Ocugen to $7 from $8 and keeps a Buy rating on the shares following the Q1 report. The firm says the company is targeting OCU400 approval in 2026.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2025-03-06
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8
2025-03-06
Reiterates
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$6 → $7
2025-03-06
Reason
Chardan Capital
Daniil Gataulin
Price Target
$6 → $7
2025-03-06
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$7 → $8
2025-02-13
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7 → $8
2025-02-13
Maintains
Strong Buy
Reason
Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 70.69% +1.20, Soho House + Co Inc (SHCO) 1.61% +0.98, X4 Pharmaceuticals (XFOR) 2.32% +0.68, Autobot Holdings (ARBE) 8.92% +0.42, Gorilla Technology Group Inc (GRRR) 35.63% +0.29, Ocugen (OCGN) 2.92% +0.28, Plug Power (PLUG) 8.36% +0.22, Equinor (EQNR) 4.81% +0.21, Hecla Mining (HL) 0.58% +0.20, and SolarEdge (SEDG) 0.83% +0.19.
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$6
2025-02-13
Reason
Chardan Capital
Daniil Gataulin
Price Target
$6
2025-02-13
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ocugen Inc (OCGN.O) is -5.24, compared to its 5-year average forward P/E of -27.18. For a more detailed relative valuation and DCF analysis to assess Ocugen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.18
Current PE
-5.24
Overvalued PE
73.31
Undervalued PE
-127.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
151.56
Current PS
0.00
Overvalued PS
383.19
Undervalued PS
-80.06
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OCGN News & Events

Events Timeline

(ET)
2025-09-15
06:04:50
Ocugen Signs Licensing Deal with Kwangdong Pharmaceutical
select
2025-08-13 (ET)
2025-08-13
06:30:53
Ocugen reports EMA positive advice for acceptability of OCU410ST
select
2025-08-08 (ET)
2025-08-08
17:05:08
Ocugen announces $20M registered direct offering of common stock, warrants
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-30Yahoo Finance
Changing Perspectives on Ocugen Following Recent Licensing and Analyst Updates

  • Analyst Price Target and Market Sentiment: Ocugen's analyst consensus price target remains steady at $9.00, reflecting confidence in the company's fair value despite a slight increase in the discount rate, indicating higher perceived risk amid sector volatility.

  • Bullish and Bearish Perspectives: Analysts express mixed sentiments, with bullish views focusing on Ocugen's long-term growth potential and management's execution, while bearish perspectives highlight concerns over increased risk and lack of immediate catalysts for growth.

  • Licensing Agreement with Kwangdong Pharmaceutical: Ocugen has secured an exclusive licensing deal for OCU400, a gene therapy for retinitis pigmentosa, which includes potential payments of up to $7.5 million and a 25% royalty on net sales in Korea.

  • Financial Metrics Overview: Key financial metrics for Ocugen, including revenue growth and net profit margin, remain unchanged, while the future P/E ratio has seen a slight increase, indicating a marginal rise in the valuation of future earnings.

[object Object]
Preview
1.0
11-20Newsfilter
Ocugen CEO to Speak at NobleCon21—21st Annual Emerging Growth Equity Conference by Noble Capital Markets

  • Ocugen Presentation Announcement: Dr. Shankar Musunuri, CEO of Ocugen, will present at NobleCon21 on December 3, 2025, discussing the company's progress towards three Biologics License Applications (BLAs) in three years and upcoming catalysts for 2026.

  • Focus on Gene Therapy: Ocugen is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a unique modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks.

  • Investor Engagement: In addition to the presentation, Ocugen's executive team will hold one-on-one meetings with investors to discuss the company's business and clinical development strategies.

  • Webcast Availability: A high-definition video webcast of the presentation will be available the day after the event on Ocugen's website and will be archived for 90 days, along with additional resources on Noble Capital Markets' platforms.

[object Object]
Preview
9.5
11-05NASDAQ.COM
Ocugen (OCGN) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ocugen Inc (OCGN) stock price today?

The current price of OCGN is 1.24 USD — it has increased 2.48 % in the last trading day.

arrow icon

What is Ocugen Inc (OCGN)'s business?

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

arrow icon

What is the price predicton of OCGN Stock?

Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ocugen Inc (OCGN)'s revenue for the last quarter?

Ocugen Inc revenue for the last quarter amounts to 1.75M USD, increased 54.23 % YoY.

arrow icon

What is Ocugen Inc (OCGN)'s earnings per share (EPS) for the last quarter?

Ocugen Inc. EPS for the last quarter amounts to -0.07 USD, increased 40.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ocugen Inc (OCGN)'s fundamentals?

The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 54.3% over the past three months. During the same period, the stock price has changed by 20.39%.
arrow icon

How many employees does Ocugen Inc (OCGN). have?

Ocugen Inc (OCGN) has 95 emplpoyees as of December 05 2025.

arrow icon

What is Ocugen Inc (OCGN) market cap?

Today OCGN has the market capitalization of 387.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free